Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia.
Blood Cells Mol Dis
; 88: 102464, 2021 05.
Article
in En
| MEDLINE
| ID: mdl-32653327
ABSTRACT
Pure red cell aplasia is a known complication after ABO incompatible stem cell transplant. Due to rarity of disease, no established treatment guidelines are available for PRCA. Daratumumab is a monoclonal antibody against CD38 expressed by plasma cells. In this report we present our experience of successfully managing a patient of post-transplant PRCA with daratumumab. Our patient had failed multiple lines of therapy prior to receiving daratumumab. Response was seen after the 3rd weekly dose of daratumumab.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Blood Group Incompatibility
/
ABO Blood-Group System
/
Red-Cell Aplasia, Pure
/
Hematopoietic Stem Cell Transplantation
/
Antineoplastic Agents, Immunological
/
Antibodies, Monoclonal
Type of study:
Etiology_studies
/
Guideline
Limits:
Adolescent
/
Female
/
Humans
Language:
En
Journal:
Blood Cells Mol Dis
Journal subject:
HEMATOLOGIA
Year:
2021
Type:
Article